Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Bladder Dysfunction Reports
Published in: Current Bladder Dysfunction Reports 3/2016

Open Access 01-09-2016 | Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

The Management of the Pediatric Neurogenic Bladder

Authors: Renea M. Sturm, Earl Y. Cheng

Published in: Current Bladder Dysfunction Reports | Issue 3/2016

Login to get access

Abstract

Neurogenic bladder is a heterogeneous entity that may result from a variety of conditions affecting the central or peripheral nervous systems. Regardless of etiology, the overall goals of management are primarily twofold. As a neurogenic bladder may affect the ability to store urine safely and to empty the bladder efficiently, early management is focused on optimization of bladder storage function to prevent irreversible injury to either the upper or lower urinary tracts. In older children, this goal is added to the challenge of maximizing quality of life through achievement of urinary continence and independence in bladder management that continues into the transition to adulthood.
In this review, we seek to bring the reader up-to-date regarding management of the pediatric neurogenic bladder with a focus on literature published in the past year. We discuss key contributions related to fetal intervention for myelomeningocele, monitoring and medical management of the neurogenic bladder and prediction of postoperative outcomes. Put together, these studies highlight the continued need for further research to improve evidence-based medical and surgical decision-making strategies for children affected by neurogenic bladder.
Literature
1.
Parker SE MC, Canfield MA, Rickard R, National Birth Defects Network, et al. Updated national birth prevalence estimates for selected birth defects in the United States, 2004–2006. Birth Defects Res A Clin MolTeratol. 2010;88(12):1008–16.CrossRef
2.
Lloyd JC, Wiener JS, Gargollo PC, Inman BA, Ross SS, Routh JC. Contemporary epidemiological trends in complex genitourinary anomalies. J Urol. 2013;190(4 Suppl):1590–5.CrossRefPubMed
3.
Sutton LN, Adzick NS, Bilaniuk LT, Johnson MP, et al. Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging. JAMA. 1999;282(19):1828–31.CrossRef
4.
Clayton DB, Tanaka ST, Trusler L, Thomas JC, et al. Long-term urological impact of fetal myelomeningocele closure. J Urol. 2011;186(4 Suppl):1581–5.CrossRefPubMed
5.
Lee NG, Gomez P, Uberoi V, Kokorowski PJ, et al. In utero closure of myelomeningocele does not improve lower urinary tract function. J Urol. 2012;188(4 Suppl):1567–71.CrossRefPubMed
6.
Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011;364(11):993–1004.CrossRefPubMedPubMedCentral
7.•
Brock JW, Carr MC, Adzick NS, Burrows PK, et al. Bladder function after fetal surgery for myelomeningocele. Pediatrics. 2015;136(4):906–13. This study presented urologic function at 12 and 30 months following a randomized prospective multi-institutional trial (MOMS) of prenatal versus neonatal closure for open myelomeningocele. No difference was observed between the two cohorts in the primary endpoint of death or meeting criteria for clean intermittent catheterization at 30 months of age.CrossRef
8.
da Cruz ML, Liguori R, Garrone G, Leslie B, et al. Categorization of bladder dynamics and treatment after fetal myelomeningocele repair: first 50 cases prospectively assessed. J Urol. 2015;193(5):1808–12.
9.
Carr M. Urological results after fetal myelomeningocele repair in pre-MOMS trial patients at the Children’s Hospital of Philadelphia. Fetal Diagn Ther. 2015;37(3):211–8.CrossRefPubMed
10.••
SnowLisy DC, Yerkes EB, Cheng EY. Update on urological management of spina bifida from prenatal diagnosis to adulthood. J Urol. 2015;194:288–96. This review provided an overview of recent literature evaluating the urologic management of spina bifida with an emphasis on outcomes following an expectant versus proactive approach to management. The authors concluded that while literature supports both approaches to protect children from renal injury, an expectant approach may increase long-term rates of bladder augmentation.CrossRef
11.
Shiroyanagi Y, Suzuki M, Matsuno D, Yamazaki Y. The significance of 99mtechnetium DMSA renal scan in children with spina bifida during long-term followup. J Urol. 2009;181(5):2262–6.CrossRefPubMed
12.
Cohen RA, Rushton HG, Belman AB, Kass EJ, et al. Renal scarring and vesicoureteral reflux in children with myelodysplasia. J Urol. 1990;144(2 Pt 2):541–5.PubMed
13.
Leonardo CR, Filgueiras MF, Vasconcelos MM, Vasconcelos R, et al. Risk factors for renal scarring in children and adolescents with lower urinary tract dysfunction. Pediatr Nephrol. 2007;22(11):1891–6.CrossRefPubMed
14.
DeLair SM, Eandi J, White MJ, Nguyen T, Stone AR, Kurzrock EA. Renal cortical deterioration in children with spinal dysraphism: analysis of risk factors. J Spinal Cord Med. 2006;30(Supp 1):30–4.
15.•
Veenboer PW, Hobbelink MG, Ruud Bosch JL, Dik P, van Asbeck FW, Beek FJ, et al. Diagnostic accuracy of Tc-99m DMSA scintigraphy and renal ultrasonography for detecting renal scarring and relative function in patients with spinal dysraphism. Neurourol Urodyn. 2015;34(6):513–8. 122 adults with spinal dysraphism who presented to a specialized clinic were prospectively evaluated with both a DMSA nuclear scan and a renal US. Significantly more renal scars were detected on DMSA with poor correlation between findings of the two radiographic tests.CrossRefPubMed
16.
Bush NC, Keays M, Adams C, Mizener K, Pritzker K, Smith W, et al. Renal damage detected by DMSA despite normal renal ultrasound in children with febrile UTI. J Pediatr Urol. 2015;11(3):126e.1. 7.CrossRef
17.
Logvinenko T, Chow JS, Nelson CP. Predictive value of specific ultrasound findings when used as a screening test for abnormalities on VCUG. J Pediatr Urol. 2015;11(4):176.e1–7.CrossRef
18.
Sturm RM, Cheng EY. Bladder wall thickness in the assessment of neurogenic bladder: a translational discussion of current clinical applications. Ann Transl Med. 2016;4(2):32–7.PubMedPubMedCentral
19.
Silva JA, Gonsalves MD, de Melo RT, Carrerette FB, Damiao R. Association between the bladder wall thickness and urodynamic findings in patients with spinal cord injury. World J Urol. 2015;33(1):131–5.CrossRefPubMed
20.
Sekerci CA, İşbilen B, Isman F, et al. Urinary NGF, TGFb1, TIMP2 and bladder wall thickness predict neurourological findings in children with myelodysplasia. J Urol. 2014;191:199–205.CrossRefPubMed
21.
Tanaka H, Matsuda M, Moriya K, et al. Ultrasonographic measurement of bladder wall thickness as a risk factor for upper urinary tract deterioration in children with myelodysplasia. J Urol. 2008;180:312–6.CrossRefPubMed
22.
Muller L, Abrahamsson K, Sillen Y, et al. Ultrasound assessment of detrusor thickness in children and young adults with spina bifida. J Urol. 2006;175:704–8.CrossRefPubMed
23.•
Kim WJ, Shiroyanagi Y, Yamazaki Y. Can bladder wall thickness predict videourodynamic findings in children with spina bifida? J Urol. 2015;194(1):180–3. Ultrasonographic measurement of bladder wall thickness of 53 children with spina bifida including 31 at specific cystometric capacities was obtained. Although specific aspects of methodology and a closely managed study population may have contributed to the outcome, no significant association was observed between BWT and high-risk urodynamic parameters.CrossRefPubMed
24.
Yamada S, Iacono RP, Andrade T, Mandybur G, Yamada BS. Pathophysiology of tethered cord syndrome. Neurosurg Clin N Am. 1995;6:311–23.PubMed
25.
Alzahrani A, Alsowayan O, Farmer JP, Capolicchio JP, Jednak R, El-Sherbiny M. Comprehensive analysis of the clinical and urodynamic outcomes of secondary tethered spinal cord before and after spinal cord untethering. J Pediatr Urol. 2015.
26.
Frainey BT, Yerkes EB, Menon VS, Gong EM, Meyer TA, Bowman RM, et al. Predictors of urinary continence following tethered cord release in children with occult spinal dysraphism. J Pediatr Urol. 2014;10(4):627–33.CrossRefPubMed
27.
Yener S, Thomas DT, Hicdonmez T, Dagcinar A, Bayri Y, Kaynak A, et al. The effect of untethering on urologic symptoms and urodynamic parameters in children with primary tethered cord syndrome. Urology. 2015;85(1):221–6.CrossRefPubMed
28.
Sawin KJ, Liu T, Ward E, Thibadeau J, et al. The national spina bifida patient registry: profile of a large cohort of participants form the first 10 clinics. J Pediatr. 2015;166(2):444–50.CrossRefPubMed
29.
Kavoussi LR, Novick AC, Partin AW, Peters CA, Campbell Walsh Urology. 10th ed, ed. W. AJ. 2012: Elsevier.
30.
Schlomer BJ, Saperston K, Baskin L. National trends in augmentation cystoplasty in the 2000s and factors associated with patient outcomes. J Urol. 2013;190(4):1352–8.CrossRefPubMed
31.
Szymanski KM, Misseri R, Whittam B, Adams CM, Kirkegaard J, King S, et al. Mortality after bladder augmentation in children with spina bifida. J Urol. 2015;193(2):643–9.CrossRefPubMed
32.
Lee JH, Kim K, Lee YS, Han SW, Kim KS, Song SH, et al. Efficacy, tolerability and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism. Korean J Urol. 2014;55(12):828–33.CrossRefPubMedPubMedCentral
33.
Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenc bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol. 1998;160:892–6.CrossRefPubMed
34.
Krause P, Fuhr U, Schnitker J, Albrecht W, et al. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. J Urol. 2013;190(5):1791–7.CrossRefPubMed
35.
Buyse G, Verpoorten C, Vereecken R, et al. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder. J Urol. 1998;160:1084–7.CrossRefPubMed
36.
Lazarus J. Intravesical application of a stable oxybutynin in the pediatric neurogenic bladder. Nat Rev Urol. 2009;6:671–4.CrossRefPubMed
37.••
Humblet M, Verpoorten C, Christiaens MH, Hirche H, et al. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourol Urodyn. 2015;34:336–42. Long-term (15 year) followup after intravesical oxybutynin administration was reported in 10 children with detrusor-sphincter dyssynergia. Intravesical oxybutynin was well tolerated with prolonged effects on compliance, capacity and suppresion of detrusor activity.CrossRefPubMed
38.
Gurocak S, Konac E, Ure I, Senol C et al. The impact of gene polymorphisms on the success of anticholinergic treatment in children with overactive bladder. Disease Markers. 2015:732686
39.
Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (Mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54:78–82.CrossRefPubMed
40.
Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L, et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol. 2004;171(2 Pt 1):845–8.CrossRefPubMed
41.
Figueroa V, Romao R, Pippi Salle JL, Koyle MA, et al. Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children. J Pediatr Urol. 2014;10(2):368–73.CrossRefPubMed
42.
Pascali MP, Mosiello G, Boldrini R, Salsano ML, Castelli E, Gennaro MD. Effects of botulinum toxin type A in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections. J Urol. 2011;185(6 Suppl):2552–7.CrossRefPubMed
43.•
Khan MK, VanderBrink B, DeFoor WR, Minevich E, et al. Botulinum toxin injection in the pediatric population with medically refractory neuropathic bladder. J Pediatr Urol, 2015. pending publication: p. 1-6. This was a retrospective series of 22 children with neurogenic bladders who were either refractory or intolerant to anticholinergics and proceeded to intravesical botox inejctions. This study evaluated predictive criteria for the response to botox injection and proposed that bladders with the highest degrees of fibrosis may be least responsive to this therapeutic option.
44.
Tiryaki S, Yagmur I, Parlar Y, Ozel K, et al. Botulinum injection is useless on fibrotic neuropathic bladders. J Pediatr Urol. 2015;11(27):1.e1–27.e4.
45.
Kim SW, Choi J, Lee YS, Han SW, Im YJ. Preoperative urodynamic factors predicting the outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity. J Urol. 2014;84(6):1480–4.CrossRef
46.
Kask M, Rintala R, Taskinen S. Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder. J Pediatr Urol. 2014;10:280–3.CrossRefPubMed
47.••
Greer T, Abbott J, Breytenbach W, McGuane D, et al, Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. J Pediatr Urol, 2015. pending publication: p. 1.e1-1.e6. This retrospective series evaluated 53 children who received multiple intravesical or intrasphincteric botox injections for varied indications. In a subset, sustained responses were observed to intravesical botox for NDO over a 10-year observation period. Additionally, 45% of children with dysfunctional voiding or DSD who received a single injection of intrasphincteric botox had a prolonged clinical response.
48.
LeNue R, Harper L, DeSeze M, Bouteiler C, et al. Evolution of the management of acquired neurogenic bladder in children using intradetrusor botulinum toxin type A injections: 5-year experience and perspectives. J Pediatr Urol. 2012;8:497–503.CrossRef
49.•
Mcnamara ER, Kurtz M, Schaeffer AJ, Logvinenko T, Nelson CP. 30-Day morbidity after augmentation enterocystoplasty and appendicovesicostomy: a NSQIP pediatric analysis. J Pediatr Urol. 2015;11:209.e1–6. This study analyzed short-term outcomes following augmentation enterocystoplasty and/or appendicovesicostomy in children from a large national sample (NSQIP) in the United States between 2012-2013. In this series of 461 patients, the composite measure of any 30-day event occurred in 28% of the cohort and was associated with surgical risk score, longer operative time and increased number of concurrent procedures.CrossRef
50.•
Du K, Mulroy E, Wallis MC, Zhang C, Presson AP, Cartwright PC. Enterocystoplasty 30-day outcomes from National Surgical Quality Improvement Program Pediatric 2012. J Pediatr Surg. 2015;50:1535–9. In this NSQIP analysis results of enterocystoplasty with or without appendicovesicostomy were provided in 2012. Outcomes were similar to those reported above. However, addition of an appendicovesicostomy or BNR were not associated with a significant increase in complication rates.CrossRefPubMed
51.
Kurtz MP, McNamara E, Schaeffer AJ, Logvinenko T, Nelson CP. Association of BMI and pediatric urologic postoperative events: results from pediatric NSQIP. J Pediatr Urol. 2015;11:224e.1–e.6.CrossRef
52.
McLeod DJ, Asti L, Mahida JB, Deans KJ, Minneci PC, Preoperative risk assessment in children undergoing major urologic surgery. J of Pediatr Urol, 2015. epub ahead of print
53.
54.
Osborn SL, Kurzrock E. Bioengineered bladder tissue—close but yet so far! J Urol. 2015;194(3):619–20.CrossRefPubMed
55.
Gill BC, Damaser M, Chermansky CJ. Future perspectives in bladder tissue engineering. Curr Bladder Dysfunct Rep. 2014;10(4):443–8.CrossRefPubMed
56.
Dave S, Salle PJ, Lorenzo AJ, Braga LHP, et al. Is long-term bladder deterioration inevitable following successful isolated bladder outlet procedures in children with neuropathic bladder dysfunction? J Urol. 2008;179:1991–6.CrossRefPubMed
57.••
Grimsby GM, Menon V, Schlomer BJ, Baker LA, et al. Long-term outcomes of bladder neck reconstruction without augmentation cystoplasty in children. J Urol. 2016;195:155–61. In this 109 patient retrospective series of varied bladder neck procedures followed for a mean of 4.9 years, 54% underwent secondary continence procedures, 18% proceeded to augmentation cystoplasty. Nearly half developed VUR or hydronephrosis and 21% renal scarring during the study period. No preoperative findings on urodynamics predicted the need for delayed augmentation although a history of vesicostomy or VUR were significnat associations.CrossRefPubMed
58.•
Snodgrass W, Granberg C, Clinical indications for augmentation in children with neurogenic urinary incontinence following bladder outlet procedures: results of a 14-year observational study. J Pediatr Urol, 2016. published ahead of print: p. 1.e1-8. This 82 patient retrospective series demonstrated feasibility and revision of surgical techniques over time in the use of a Leadbetter/Mitchell bladder neck revision with sling as compared to later use of a bladder neck sling alone that significantly improved continence outcomes in the absence of augmentation cystoplasty. While 12% of children in this series after a mean followup of 60 months proceeded to augmentation cystoplasty, no preoperative UDS parameter predicted need for subsequent augmentation.
59.•
Whittam B, Szymanski K, Misseri R, Carroll A, Kaefer M, Rink R, et al. Long-term fate of the bladder after isolated bladder neck procedure. J Pediatr Urol. 2014;10:886–91. In this retrospective series of 29 individuals who underwent bladder neck procedrues followed for a mean of 8.9 yearss, 45% proceeded to a delayed augmentation cystoplasty. Although preoperative UDS findings did not correlate with outcomes, those who underwent delayed augment had smaller capacity bladders and poorer compliance following BNR.CrossRefPubMed
60.
Murthy P, Cohn J, Seliq RB, Gundeti MS. Robot-assisted laparoscopic augmentation ileocystoplasty and mitrofanoff appendicovesicostomy in children: updated interim results. Eur Urol. 2015;68(6):1069–75.CrossRefPubMed
61.
Flum AS, Zhao L, Kielb SJ, Wilson EB, Shu T, Hairston JC. Completely intracorporal robotic-assisted laparoscopic augmentation enterocystoplasty with continent catheterizable channel. Urology. 2014;84(6):1314–8.CrossRefPubMed
62.
Grimsby GM, Jacobs M, Gargollo PC. Comparison of complications of robot-assisted laparoscopic and open appendicovesicostomy in children. J Urol. 2015;194(3):772–6.CrossRefPubMed
63.
Gargollo PC. Robotic-assisted bladder neck repair: feasibility and outcomes. Urol Clin North Amer. 2015;42(1):111–20.CrossRef
64.
Grimsby GM, Jacobs M, Menon V, Schlomer BJ, Gargollo PC, Perioperative and short-term outcomes of robotic versus open bladder neck procedures in patients with neurogenic incontinence. J Urol, 2015. Epub ahead of print: p. 1-5.
65.
Faasse MA, Lindgren B, Frainey BT, Marcus CR, Szcodry DM, Glaser AP, et al. Perioperative effects of caudal and transversus abdominis plane (TAP) blocks for children undergoing urologic robot-assisted laparoscopic surgery. J Pedatr Urol. 2015;11(3):121.e1–e7.CrossRef
66.
Szymanski KM, Misseri R, Whittam B, Raposo SM, King SJ, Kaefer M, et al. Quality of life assessment in spina bifida for adults (QUALAS-A): development and international validation of a novel health-related quality of life instrument. Qual Life Res. 2015;24(10):2355–64.CrossRefPubMed
67.••
Szymanski KM, Misseri R, Whittam B, Yang DY, Raposo SM, King S, et al. Quality of life assessment in spina bifida for children (QUALAS-C): development and validation of a novel health-related quality of life instrument. Urology. 2016;87:178–84. This study described the development and validation of QUALAS-C which is a brief questionnaire developed in 8 to 12 year old children with spina bifida in the assessment of health related quality of life, bowel and bladder function.CrossRefPubMed
68.
Hubert KC, Sideridis G, Sherlock R, Queally J, Rosoklija I, Kringle G, et al. Validation of a bowel dysfunction instrument for adolescents with spina bifida. J Pediatr Urol. 2015;11(4):199.e1–e7.CrossRef
69.
Hubert KC, Sideridis G, Sherlock R, Rosoklija I, Kringle G, Johnson K, et al. Urinary incontinence in spina bifida: initial instrument validation. Res Dev Disabil. 2015;40:42–50.CrossRefPubMed
70.
Fischer N, Church P, Lyons J, McPherson AC. A qualitative exploration of the experiences of children with spina bifida and their parents around incontinence and social participation. Child Care Health Dev. 2015;41(6):954–62.CrossRefPubMed
71.
Holland JE, DeMaso D, Rosoklija I, Johnson KL, Manning D, Bellows AL, et al. Self-cathing experience journal: enhancing the patient and family experience in clean intermittent catheterization. J Pediatr Urol. 2015;11(4):187.e1–6.CrossRef
72.
Sturm R, Y.J., Durbin-Johnson B, Kurzrock E, Use of a diurnal indwelling catheter to improve quality of life for patients with spinal cord disorders, in ESPU. 2015: Prague.
73.
Szymanski KM, Misseri R, Whittam B, Large T, Cain MP. Current opinions regarding care of the mature pediatric urology patient. J Pediatr Urol. 2015;11(5):251.e1–e4.CrossRef
74.
Shalaby MS, Gibson A, Granitsiotis P, Conn G, Cascio S. Assessment of the introduction of an adolescent transition urology clinic using a validated questionnaire. J Pediatr Urol. 2015;11(2):89.e1–e5.CrossRef
Metadata
Title
The Management of the Pediatric Neurogenic Bladder
Authors
Renea M. Sturm
Earl Y. Cheng
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Bladder Dysfunction Reports / Issue 3/2016
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-016-0371-6

Other articles of this Issue 3/2016

Current Bladder Dysfunction Reports 3/2016 Go to the issue

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

Sacral Neuromodulation for Bladder Dysfunction in Children: Indications, Results and Complications

Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)

Psychotropic Drugs and Their Effects on Lower Urinary Tract Function: an Update

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

Management of Bladder Diverticula in the Pediatric Population

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

The Robotic Appendicovesicostomy and Bladder Augmentation

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

Modified O’Regan Protocol for Overactive Bladder

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Vulvodynia: Current Etiology, Diagnosis, and Treatment